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BACKGROUND: Since 2013, the residents of the city of Vantaa, and 20 to 29 years (adjusted incidence rate ratio, 1.35; 95% confidence
Finland, have been offered their first long-acting reversible contraceptive
method (levonorgestrel-releasing intrauterine system, implant, and copper
intrauterine device) free of charge.
OBJECTIVE: The primary aim of this study was to assess the 2-year
cumulative discontinuation rates of long-acting reversible contraceptive
methods when provided free of charge for first-time users in a real-world
setting. Additional aims were to describe factors associated with
discontinuation and to evaluate the reasons for discontinuation.
STUDYDESIGN: This is a retrospective register-based cohort study of
2026 nonsterilized women aged 15 to 44 years, who initiated a free-of-
charge long-acting contraceptive method in 2013e2014 in the city of
Vantaa. Removals within 2 years after method initiation and reasons for
discontinuation were obtained from electronic health records and from
national registers. We calculated the 2-year cumulative incidence rates of
discontinuation with 95% confidence intervals for each method.
Furthermore, we assessed crude and adjusted incidence rate ratios of
discontinuation with 95% confidence interval by Poisson regression
models comparing implants and copper intrauterine device with
levonorgestrel-releasing intrauterine systems.
RESULTS: During the 2 -year follow-up, 514 women discontinued,
yielding a cumulative discontinuation rate of 28.3 per 100 women-years
(95% confidence interval, 26.2e30.4). Among the 1199 women who
initiated the levonorgestrel-releasing intrauterine system, the cumulative
discontinuation rate was 24.2 per 100 women-years (95% confidence
interval, 21.7e26.9); among the 642 implant users, 33.3 per 100
women-years (95% confidence interval, 29.5e37.4); and among the 185
copper intrauterine device users, 37.8 per 100 women-years (95%
confidence interval, 31.0e45.7).
Compared with women aged 30 to 44 years, women aged 15 to 19 years
(adjusted incidence rate ratio, 1.58; 95% confidence interval, 1.17e2.14)Cite this article as: Saloranta TH, Gyllenberg FK, But A,
et al. Free-of-charge long-acting reversible
contraception: two-year discontinuation, its risk factors,
and reasons. Am J Obstet Gynecol 2020;XX:x.exex.ex.
0002-9378/$36.00
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https://doi.org/10.1016/j.ajog.2020.06.023interval, 1.11e1.63) were more likely to discontinue. We observed a
higher discontinuation rate in women who had given birth within the
previous year (adjusted incidence rate ratio, 1.36; 95% confidence in-
terval, 1.13e1.65), spoke a native language other than Finnish or
Swedish (adjusted incidence rate ratio, 1.31; 95% confidence interval,
1.06e1.63), and had a history of a sexually transmitted infection (adjusted
incidence rate ratio, 1.62; 95% confidence interval, 1.07e2.46). No
association was found in marital status, overall parity, history of induced
abortion, socioeconomic status, education level, or smoking status.
The most common reason for discontinuation was bleeding disturbances,
reported by 21% of women who discontinued the levonorgestrel-releasing
intrauterine system, by 71% who discontinued the implant, and by 41%
who discontinued the copper intrauterine device. One in 4 women who
discontinued the copper intrauterine device reported heavy menstrual
bleeding, whereas only 1% who discontinued the levonorgestrel-releasing
intrauterine system and none who discontinued implants reported this
reason. Abdominal pain was the reported reason for discontinuation in
20% of both intrauterine device users and in only 2% who discontinued
implants.
CONCLUSION: At 2 years, the use of implants and copper intrauterine
devices was more likely to be discontinued than that of the levonorgestrel-
releasing intrauterine system. Women younger than 30 years and those
who gave birth in the preceding year, spoke a native language other than
Finnish or Swedish, or had a history of sexually transmitted infections were
more likely to discontinue. The levonorgestrel-releasing intrauterine sys-
tem was least likely to be removed owing to bleeding disturbances.
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copper intrauterine devices, discontinuation, family planning, intrauterine
devices, levonorgestrel-releasing intrauterine systemiscontinuation of oral contracep-D tion is common, with approxi-
mately 45% to 55% of women
discontinuing within the first 6 to 12
months.1,2 Notably lower discontinua-
tion rates have been reported for long-acting reversible contraceptive (LARC)
methods, that is, the levonorgestrel-
releasing intrauterine system (LNG-
IUS), implants, and copper intrauterine
devices (Cu-IUDs).1,3e5 However, pre-
vious studies have reported conflicting
results on the discontinuation rates of
individual LARCmethods and on factors
associated with discontinuation.1,3,5e8
In the city of Vantaa, in Helsinki’s
metropolitan area, Finland, women have
been offered their first LARC method
free of charge since 2013. We have pre-
viously reported that uptake of LARC
methods increased and rates of inducedMONTH 2020 Amabortion declined after the introduction
of this public program.9
For implementation of programs of-
fering free-of-charge LARCmethods, it is
essential to evaluate the discontinuation
rates of different LARC methods, espe-
cially because the results on discontinu-
ation vary and discontinuation is a key
determinant of cost efficacy.10 It is equally
important to have data on discontinua-
tion rates to ensure adequate resources to
provide easy access to LARC removal and
ascertain reproductive autonomy.
The primary aim of this study was to
assess the 2-year discontinuation rates oferican Journal of Obstetrics & Gynecology 1.e1
AJOG at a Glance
Why was this study conducted?
This study aimed to evaluate the 2-year cumulative discontinuation of long-
acting reversible contraceptive (LARC) methods provided free of charge in a
real-world setting.
Key findings
The 2-year cumulative discontinuation of free-of-charge LARCmethods was 28%
(95% confidence interval [CI], 26e30). The levonorgestrel-releasing intrauterine
system (LNG-IUS) had the lowest 2-year cumulative discontinuation. The
following characteristics were associated with higher rates of discontinuation: age
under 30 years, delivery within a year preceding LARC initiation, nonnational
native language, and history of a sexually transmitted infection (STI). Implants
and copper intrauterine devices (Cu-IUDs) were more likely to be discontinued
because of bleeding disturbances than the LNG-IUS.
What does this add to what is known?
We found similar 2-year cumulative discontinuation of LARC methods when
offered free of charge as reported previously with mixed-payer settings. Our
findings emphasize the importance of an acceptable bleeding profile because
bleeding disturbances were the most common reason for discontinuation.
Original Research GYNECOLOGY ajog.orgdifferent LARC methods among women
initiating their first free-of-charge LARC
method in the city of Vantaa in
2013e2014. The secondary aims were to
describe factors associated with discon-
tinuation and to evaluate the reasons for
discontinuation.
Materials and Methods
In this retrospective register-based cohort
study, we studied the discontinuation rate
among women who initiated their first
free-of-charge LARC method in
2013e2014 in the city of Vantaa, Finland.
According to the FinnishHealth Care Act,
all preventive care visits—including con-
traceptive services—are offered without
charges in public healthcare services.11
The contraceptive methods are not
reimbursed. Approximately 210,000 in-
habitants in the city of Vantaa are offered
contraceptive services in centralized
family planning clinics within primary
healthcare services. The clinics are
frequently visited by 20% of
reproductive-aged women using the ser-
vices annually.9 Private healthcare is also
available and is partially covered by the
National Health Insurance.12 About 18%
of women of all ages in the city of Vantaa
visited a private obstetrician-gynecologist
in 2013.13 There are no data available on1.e2 American Journal of Obstetrics & Gynecologywhich proportion of these visits were
related to contraception.
Since 2013, all women in Vantaa have
been offered their first free-of-charge
LARC method at public family planning
clinics. Available LARC methods in
2013e2014 were the 52-mg LNG-IUS,
13.5-mg LNG-IUS (since 2014), 380-
mm2 Cu-IUD, and the levonorgestrel- or
etonogestrel-releasing implants. At the
time of the study, the 52-mg LNG-IUS,
levonorgestrel- releasing implants, and
Cu-IUD were recommended for 5-year
use, and the 13.5-mg LNG-IUS and
etonogestrel-releasing implants were
advised for3-yearuse. In addition toLARC
methods, women aged younger than 20
years received a 9-month supply of oral
contraceptives or contraceptive rings, and
all women received a 3-month supply
when initiating or switching a method.
We identified 3210 women with at
least 1 LARC insertion at the family
planning clinics. Only the first LARCwas
included in the analyses. After applying
exclusion criteria (Figure 1), the study
cohort included 2026 nonsterilized fe-
male residents of Vantaa initiating their
first LARC free of charge at the age of 15
to 44 years between 2013 and 2014.
Women who purchased LARC them-
selves were excluded because they wereMONTH 2020likely to represent a different group of
women than first-time LARC users.
We identified LARC insertions from
electronic patient records of family
planning clinics based on a code, which
is used to compensate general practi-
tioners for LARC insertion. Data were
extracted and reviewed by 3 researchers
(T.H.S. and F.K.G. and a research nurse)
between February 02, 2016, and
December 20, 2017. The data included
insertion date, whether the method was
provided free of charge, brand of the
device, date of LARC removal, reasons
for removal, and smoking status as
entered in the electronic patient records
within 2 years before LARC insertion.
In Finland, different registers can be
combined using a personal identification
number assigned for every citizen since
the 1960s. The Finnish Institute of
Health and Welfare (THL) registers data
on births, induced abortions, steriliza-
tions, sexually transmitted infections
(STIs), hospital outpatient visits, and
inpatient care episodes. The registers are
of high quality and validated.14e16 All
cases of chlamydia, syphilis, and gonor-
rhea must be reported to the register on
infectious diseases. The register on hos-
pital outpatient visits and inpatient care
episodes collects information on the
10th revision of the International Sta-
tistical Classification of Diseases and
Related Health Problems (ICD-10) and
International Classification of Primary
Care diagnoses and the medical and
surgical procedures according to the
Classification of Surgical Procedures of
the Nordic Medico-Statistical Commit-
tee at all visits.
We obtained data on sterilizations,
births, induced abortions, STIs, and
outpatient visits and hospital-care epi-
sodes in obstetrics and gynecology from
the registers maintained by the THL. The
Central Population Register of Vantaa
provided the data on date of birth,
marital status, native language, death,
and migration from the city of Vantaa.
Because ethnicity or race cannot be
registered in Finland, we used data on
mother tongue to represent ethnic vari-
ation. We obtained data on education
and socioeconomic status from Statistics
Finland. Educational status was divided
FIGURE 1
Formation of the study cohort of women receiving a free-of-charge long-
acting reversible contraceptive method
LARCs inserted for residents of city of Vantaa in 
2013–2014 (n=3210)










- Women aged 45 years or more at the time of 
insertion (n=229)
- Women with prior sterilization (n=7)
- Women who purchased the LARC themselves 
(n=886) or the LARC cost was unknown 
(n=53)
- Women who had moved away from Vantaa 
prior to LARC insertion (n=8)
- One woman that became pregnant around the 
time the Cu-IUD was inserted and had no exact 
date of removal and hence the estimates used 
lead to a negative time of follow-up
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
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attainment above basic education and no
educational attainment, and socioeco-
nomic status in 6 categories according to
Statistic Finland’s standards (Table 1).
Age was divided into the following 3
categories: 15 to 19, 20 to 29, and 30 to
44 years. History of induced abortion or
delivery, history of STI 2 years before the
LARC insertion, marital status, and
native language were analyzed as
dichotomous variables.
Start of follow-up was defined as the
date of the first LARC insertion during the
study period.Endof follow-upwasdefined
as thefirst of anyof the following censoring
events: LARCremoval (n¼514),migration
from Vantaa (n¼287), death (n¼0), data
extraction date (n¼17), 2 years of LARCmethod use, or on August 6, 2016
(n¼269), that is, 21 weeks before the end
of 2016. This allowed for all pregnancies to
be detected from the data on the universal
ultrasound screening program or the
abortion registry.
LARC removals were identified from
the electronic records or concluded us-
ing data from national registers. LARC
removal was defined as the first of any of
the following events: removal according
to the family planning clinic records
(n¼473), a hospital visit with a proced-
ure code indicating removal of the LARC
method (n¼22), sterilization (n¼3),
start of a pregnancy ending in an
induced abortion (n¼1), or removal
estimated from a hospital visit with a
pregnancy-related diagnosis orMONTH 2020 Amprocedure code (n¼15). Of the 473 re-
movals in the family planning clinic re-
cords, 21 lacked the date of removal,
which was estimated as having occurred
halfway between the last notion of the
device being in place and the time it was
recorded as having been removed. For
the removals identified from hospital
registers, the reason for removal was
classified according to the ICD-10 code
at the removal visit.
In Finland, all pregnant women are
offered an early pregnancy ultrasound
scan between 10 and 13 6/7 weeks’
gestation and receive a structural ultra-
sound scan between 19 and 21 weeks’
gestation.17 These visits are identifiable
from the records of outpatient visits.
Notably, 8 women without a recorded
removal in the electronic patient record
presented for early pregnancy ultra-
sound. We estimated the removal date
for these women by calculating the mean
time from LARC removal for pregnancy
intentions until the date of an ultrasound
scan (205 days). We calculated similar
estimates for women presenting with
visits for early pregnancy-related diag-
nosis (250 days, n¼3) or miscarriage
(156 days, n¼4).
We defined women with no registered
LARC removal or censoring event as
continuers of their method. Because
outpatient procedures in private health-
care are not nationally registered, we
lacked information on possible LARC
removals in private healthcare if a
woman had no event indicating removal
in public healthcare afterward.
Statistical methods
We calculated the 2-year cumulative
discontinuation incidences with
95% confidence intervals (CIs). We
plotted cumulative discontinuation inci-
dence curves by LARC method and by
factors associated with discontinuation.
The differences between cumulative
discontinuation incidence curves were
assessed using the log-rank test. We used
Poisson regression to calculate crude and
adjusted incidence rate ratios (IRR) for
discontinuation. We selected variables to
multivariate model if they were signifi-
cantly associated (P < .05) with discon-
tinuation in univariate analysis and iferican Journal of Obstetrics & Gynecology 1.e3
TABLE 1










Median (IQR) 28.6 (23.1e33.4) 30.7 (25.7e35.0) 23.2 (19.5e29.2) 28.5 (25.0e32.7)
Age categories, y <.001
15e19 237 (12) 49 (4) 183 (29) 5 (3)
20e29 922 (46) 502 (42) 314 (49) 106 (57)
30e44 867 (43) 648 (54) 145 (23) 74 (40)
Married 802 (40) 563 (47) 155 (24) 84 (45) <.001
History of delivery 1,304 (64) 953 (79) 225 (35) 126 (68) <.001
Delivery in the year preceding LARC initiation 774 (38) 557 (46) 147 (23) 70 (38) <.001
History of induced abortion 479 (24) 309 (26) 120 (19) 50 (27) .002
Induced abortion in the year preceding
LARC initiation
163 (8) 89 (7) 53 (8) 21 (11) .183
Socioeconomic statusb
Upper level employees 224 (11) 166 (14) 34 (5) 24 (13) 176 (12)
Lower level employees or manual workers 1,171 (58) 728 (61) 340 (53) 103 (56) 886 (59)
Entrepreneurs, pensioners, or unknown 206 (10) 120 (10) 69 (11) 17 (9) 147 (10)
Students 287 (14) 105 (9) 157 (24) 25 (14) 210 (14)
Long-term unemployed 128 (6) 74 (6) 39 (6) 15 (8) 85 (6)
Unavailable 10 (0) 6 (1) 3 (0) 1 (1) 8 (1)
Education level <.001
Basic (9-y mandatory education) or unknownc 596 (29) 269 (22) 279 (43) 48 (26)
Longer (10 y or more) 1,430 (71) 930 (78) 363 (57) 137 (74)
Only basic education among women aged
25 y or more
255 (13) 165 (14) 54 (8) 36 (19) <.001
Native language, Finnish or Swedish 1,669 (82) 1,008 (84) 539 (84) 122 (66) <.001
Sexually transmitted infectiond 61 (3) 25 (2) 34 (5) 2 (1) <.001
Smokinge <.001
Yes 422 (21) 204 (17) 187 (29) 31 (17)
No 1,186 (59) 718 (60) 367 (57) 101 (55)
Missing 418 (21) 277 (23) 88 (14) 53 (29)
Data are expressed as n (%) unless otherwise mentioned.
Cu-IUD, copper intrauterine device; IQR, interquartile range; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
a KruskaleWallis test for continuous variables and c2-test for categorical variables; b Socioeconomic status of the youngest age group can be derived from their family’s socioeconomic status;
c Comprises women with only basic education and without education in Finland and those not graduating from elementary school; d Chlamydia, gonorrhea, or syphilis 2 years before LARC initiation;
e As entered in the electronic patient records within 2 years before LARC insertion.
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by decreasing the Akaike information
criterion and the variable was statistically
significant (P < .05) in the multivariate
model. We calculated frequencies of
discontinuation reasons for each method
and compared the frequencies using chi-1.e4 American Journal of Obstetrics & Gynecologysquare analysis. Statistical significance
was set at the 5% level. All analyses were
conducted using the statistical software R
3.4.3 (R Foundation for Statistical
Computing, Vienna, Austria).18
We performed several sensitivity ana-
lyses. In the primary analysis, correlationMONTH 2020among age, basic education, and socio-
economic status precluded the assess-
ment of their effect on LARC
discontinuation with the multivariate
Poisson regression model. To check
whether basic education and socioeco-
nomic status were associated with
FIGURE 2
Cumulative 2-year discontinuation of LARC methods
Cu-IUD
Cu-IUD
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
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performed age-stratified analysis using
the final Poisson model but excluding
age. To inspect whether discontinuation
rates were similar among women revis-
iting the clinics after the initiation, we
calculated the 2-year cumulative
discontinuation and IRRs for 58% of
womenwith recorded visits in the clinics
within 2 years after LARC initiation. To
evaluate the influence of age distribu-
tion, we also calculated and illustrated
the cumulative discontinuation in age
groups and repeated the univariate and
multivariate Poisson modeling
excluding women aged 15 to 19 years.
We received approval from the ethics
committee of the Hospital District of
Helsinki and Uusimaa. The register-
keeping organizations approved the use
of the health register data in this study.
We followed the Strengthening the
Reporting of Observational Studies in
Epidemiology guidelines in the manu-
script preparation and study design.
Results
Of all LARC methods initiated free of
charge (n¼2026), 1199 women (59%)
chose the LNG-IUS. Because only 124
(10%) women chose the 13.5-mg LNG-
IUS and 1075 (90%) chose the 52-mg
LNG-IUS, both LNG-IUSs were com-
bined for the analyses. Of the 642 (32%)
women initiating an implant, 9 (1%)
chose levonorgestrel-containing implants
and 633 (99%) chose etonogestrel-
containing implants. Implants were also
combined for the analyses. The Cu-IUD
was selected by 185 (9%) women.
Women choosing implants were
younger, more often nulliparous, un-
married, smokedmore often, more often
had only basic education, and more
often had a history of an STI 2 years
before LARC initiation thanwomenwho
chose the LNG-IUS or Cu-IUDs
(Table 1). Women who chose Cu-IUDs
more often spoke a native language
other than Finnish or Swedish than
women who chose the LNG-IUS. Char-
acteristics divided according to method
and continuation status are presented in
Supplemental Table 1.
During the median follow-up of 1.9
years (interquartile range, 1.0e2.0), 514women discontinued, yielding a 2-year
cumulative discontinuation rate in the
whole cohort of 28.3 per 100 women-
years (95% CI, 26.2e30.4). Of those
who discontinued, 263 were LNG-IUS
users, 187 were implant users, and 64
were Cu-IUD users. The LNG-IUS had
the lowest cumulative discontinuation at
2 years (24.2 per 100 women-years; 95%
CI, 21.7e26.9), followed by implants
(33.3 per 100 women-years; 95% CI,
29.5e37.4) and Cu-IUDs (37.8 per 100
women-years; 95% CI, 31.0e45.7). The
differences between the LNG-IUS and
Cu-IUD cumulative discontinuation
incidence curves were statistically sig-
nificant (P<.001) (Figure 2).
The crude IRRs for discontinuation
during the first 2 years were 1.38 (95%
CI 1.15e1.67) for implants and 1.80
(95% CI 1.37e2.37) for Cu-IUDs
compared with the LNG-IUS. Univari-
ate analyses (Table 2, Figure 3) indi-
cated a statistically significant differenceMONTH 2020 Am(P < .05) in LARC discontinuation rate
according to categorical age, delivery in
the year preceding LARC insertion,
native language, history of STI 2 years
before LARC insertion, socioeconomic
status, and having only basic education.
Age was strongly associated with so-
cioeconomic status and basic educa-
tion, and thus, socioeconomic status
and basic education were not included
in the final multivariate model. Marital
status, parity, history of abortion, hav-
ing only basic education at the age of
25 years or above, and smoking status
were not significantly associated (P <
.05) with discontinuation.
After adjustment, the IRRs for
discontinuation were 1.29 (95% CI,
1.05e1.58) for implants and 1.68 (95%
CI, 1.27e2.22) for Cu-IUDs compared
with the LNG-IUS. Compared with
women at the age of 30 to 44 years,
women aged 15 to 19 years (IRR, 1.58;
95% CI, 1.17e2.14) and 20 to 29 years oferican Journal of Obstetrics & Gynecology 1.e5
TABLE 2
Crude and adjusted Poisson regression estimates of 2-year discontinuation rate ratios with Cu-IUD and implant
compared with LNG-IUS, and characteristics associated with discontinuation of all LARC methods (n[2026)
Crude rate ratio (95% CI) P value Adjusted rate ratio (95% CI)a P value
LARC method
LNG-IUS Ref. Ref.
Implant 1.38 (1.15e1.67) <.001 1.29 (1.05e1.58) .017
Cu-IUD 1.80 (1.37e2.37) <.001 1.68 (1.27e2.22) <.001
Aged 30e44 y Ref. Ref.
Aged 20e29 y 1.46 (1.21e1.76) <.001 1.35 (1.11e1.63) .003
Aged 15e19 y 1.58 (1.20e2.07) .001 1.58 (1.17e2.14) .003
Delivery in the year preceding LARC initiation
No Ref. Ref.
Yes 1.23 (1.05e1.48) .013 1.36 (1.13e1.65) .001
Native language, Finnish or Swedish
Yes Ref. Ref.
No 1.41 (1.15e1.74) .001 1.31 (1.06e1.63) .012
Sexually transmitted infectionb
No Ref. Ref.
Yes 1.69 (1.12e2.55) .012 1.62 (1.07e2.46) .023
Socioeconomic statusc
Upper level employees Ref.
Lower level employees or manual workers 1.14 (0.84e1.55) .406
Entrepreneurs, pensioners, or unknown 1.31 (0.90e1.92) .163
Students 1.30 (0.91e1.87) .153
Long-term unemployed 1.67 (1.11e2.52) .015
Unavailable 1.15 (0.28e4.73) .846
Education level
Longer (10 y or more) Ref.
Basic (9-y mandatory education) or unknownd 1.34 (1.11e1.60) .002
Marital status
Married Ref.
Not married 0.98 (0.82e1.16) .78
History of delivery
No Ref.
Yes 1.05 (0.87e1.26) .631
History of induced abortion
No Ref.
Yes 0.93 (0.76e1.14) .475
Induced abortion in the year preceding LARC initiation
No Ref.
Yes 1.08 (0.80e1.47) .621
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TABLE 2
Crude and adjusted Poisson regression estimates of 2-year discontinuation rate ratios with Cu-IUD and implant
compared with LNG-IUS, and characteristics associated with discontinuation of all LARC methods (n[2026) (continued)
Crude rate ratio (95% CI) P value Adjusted rate ratio (95% CI)a P value
Only basic education among women aged 25 y or more
No Ref.
Yes 1.20 (0.94e1.54) .134
Smoking within the past 2 ye
No Ref.
Yes 0.95 (0.76e1.19) .651
CI, confidence interval; Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system; Ref., reference.
a Adjusted with categorical age, delivery in the year preceding LARC initiation, mother tongue, and STI 2 years before LARC initiation; b Chlamydia, gonorrhea, or syphilis 2 years before LARC
initiation; c Socioeconomic status of the youngest age group can be derived from their family’s socioeconomic status; d Comprises women with only basic education and without education in Finland
and those not graduating from elementary school; e As entered in the electronic patient records within 2 years before LARC insertion.
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more likely to discontinue.We observed a
higher discontinuation rate for women
who had delivered within the previous
year (IRR, 1.36; 95% CI, 1.13e1.65),
spoke a native language other than
Finnish or Swedish (IRR, 1.31; 95% CI
1.06e1.63), and had history of an STI
(IRR, 1.62; 95% CI, 1.07e2.46).
The most common reason for
discontinuation was bleeding distur-
bances, reported by 21% of women who
discontinued the LNG-IUS, by 71%
who discontinued implants, and by
41% who discontinued Cu-IUDs.
Among women who discontinued Cu-
IUDs, 27% discontinued because of
heavy menstrual bleeding, whereas only
1%who discontinued the LNG-IUS and
none who discontinued implants re-
ported this reason. Abdominal pain was
the reported reason for discontinuation
for 20% of both IUD and IUS users
compared with 2% of women who dis-
continued implants (Table 3).
In the sensitivity analyses, we found no
significant association of socioeconomic
status or basic education with discontin-
uation in the age-stratified analysis. The
method-specific IRRs calculated for 58%
of women who visited the family plan-
ning clinics during follow-upwere similar
to those assessed from the whole study
population, but the cumulative discon-
tinuation incidences were much higher
(Supplemental Table 2, SupplementalFigure 1). In age-stratified analysis, the
crude cumulative discontinuation rate of
the LNG-IUS was lower than that of im-
plants and Cu-IUDs inwomen aged 20 to
29 years. The differences in other age
groups were parallel but not statistically
significant (Supplemental Table 3,
Supplemental Figure 2). The same vari-
ables remained associated with discon-
tinuation in the Poisson model excluding




We found that the discontinuation rate
of the LNG-IUS was lower than that of
implants and Cu-IUDs when LARC
methods were provided free of charge in
a primary care setting. Education and
socioeconomic status were not associ-
ated with discontinuation; neither were
parity nor history of abortion. Age
below 30 years, delivery within the year
preceding LARC insertion, speaking a
native language other than the national
languages Finnish and Swedish, and
having a history of STI were associated
with discontinuation of the LARC
method within 2 years of insertion.
Bleeding disturbances were the most
common reason for discontinuation.
Implants and Cu-IUDs were dis-
continued because of bleeding distur-
bances 2 to 4 times more often than was
the LNG-IUS.MONTH 2020 AmResults
The higher discontinuation rates of im-
plants than of the LNG-IUS are in
agreement with the findings from the
CHOICE study.3 However, in contrast to
our findings, the rates of discontinuation
in the CHOICE study were similar for
Cu-IUDs and the LNG-IUS.3 These
findings can be influenced by age dis-
tribution of the users. Because young
women more often discontinue and
more often choose implants, this can
bias implant discontinuation rates so
that they are higher than intrauterine
methods chosen more often by older
women.3,6e8 In this study, women who
chose Cu-IUDs were younger than
women who chose the LNG-IUS, which
could have affected the discontinuation
rate of Cu-IUDs so that it was higher
than in previous studies, in which
women who chose Cu-IUDs were in the
same age or older than women who
chose the LNG-IUS.1,3,6,7 However, the
differences between methods remained
considerable even after adjusting for age
in this study.
The finding that education and socio-
economic status were not associated with
discontinuation is in line with the results
of previous studies and is reassuring
because these do not seem to affect a
woman’s reproductive autonomy.3,7
There are conflicting findings concern-
ing the effect of parity on discontinuation
of LARC use.3,6,7 Reassuringly, parity waserican Journal of Obstetrics & Gynecology 1.e7
FIGURE 3
Cumulative discontinuation of LARC methods according to A, age, B, delivery within the preceding year, C, mother
tongue, and D, history of STI
A B
C DDelivery in the year preceding LARC initiation
Native language
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system; STI, sexually transmitted infection.
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this study. Similarly, as in the CHOICE
study, we found that womenwith a recent
history of STI were at higher risk for
discontinuation.3 Women with a native
language other than the national lan-
guages had higher rates of discontinua-
tion. Women with nonnational native
language in Finland are a heterogenous1.e8 American Journal of Obstetrics & Gynecologygroup, but they all presumably received
counseling in a language other than their
native tongue. This could have had an
effect leading to higher rates of
discontinuation.
Up to 52 (78%) LNG-IUS and implant
users experience unscheduled bleeding,
but unlike with implants, the unfavorable
bleeding patterns of the LNG-IUS tend toMONTH 2020subside when continuing their use.19 In
line with previous studies, we also found
that implant discontinuation for bleeding
disturbances was more likely than
discontinuation of the LNG-IUS.20,21
Clinical implications
Counseling women on expected bleeding
patterns associated with LNG-IUS use is
TABLE 3
Reasons for discontinuation of all free-of-charge LARC methods and by method type within 2 years after LARC
initiation, with frequencies among those who discontinued
Any LARC LNG-IUS Implant Cu-IUD
P value for differences
between methodsa
No. of discontinuations 514 263 187 64
Wished to conceive 84 (16) 60 (23) 13 (7) 11 (17) .004
Bleeding disturbancesb 214 (42) 55 (21) 133 (71) 26 (41) <.001
Heavy menstrual bleeding 21 (4) 3 (0) 1 (1) 17 (27) <.001
Abdominal pain or cramping 69 (13) 52 (20) 4 (2) 13 (20) <.001
Infection, including vaginal infections and PID 16 (3) 13 (5) 1 (1) 2 (3) .09
Mood 27 (5) 14 (5) 12 (6) 1 (2) .281
Skin problems (eg, acne) 37 (7) 24 (9) 12 (6) 1 (2) .383
Weight gain 25 (5) 14 (5) 11 (6) 0 (0) .168
Expulsion or partial expulsion 49 (10) 42 (16) 0 (0) 7 (11) <.001
Problems with libido 17 (6) 12 (5) 5 (3) 0 (0) .373
Other or unknown reasonsc 52 (20) 29 (11) 17 (9) 6 (9) .794
Data are expressed as n (%) unless otherwise mentioned.
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system; PID, pelvic inflammatory disease.
a P value obtained by chi-squared test; b Including irregular bleeding, heavy bleeding, and amenorrhea; c Unknown (n¼26).
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rates.22 In our data, bleeding disturbances
were the most common reason for
discontinuation with the LNG-IUS and
even more common with implants and
Cu-IUDs. Only 16% of women dis-
continued because of pregnancy in-
tentions, which implies a continuing need
for contraception after discontinuation of
LARC. Although the overall discontinua-
tionof LARCmethods is low,womenwho
discontinue their first device because of
adverse effects are unlikely to reinitiate the
same method,10,23,24 which limits their
future contraceptive options andmay lead
to the use of less effective methods. This
emphasizes the importance of adequate
resources to provide for counseling on the
expected bleeding patterns during the use
of LARC methods.
Research implications
Additional comparative data on discon-
tinuation rates among LARCmethods are
needed to better understand continuation
and cost efficacy in different settings.
Further studies are needed to assess fac-
tors associated with discontinuation toprovide means for more individualized
and woman-centered contraceptive care.
Strengths and limitations
Evaluating the discontinuation rates in a
real-life setting is challenging because
regular follow-up visits are no longer
recommended for satisfied LARC
users.25,26 Continuing LARC use is not
systematically recorded in the general
medical patient records. Hence,
excluding women with no data on
continuing LARC use would over-
estimate the discontinuation rates. Thus,
we assumed that women still living in
Vantaa and without contacts to primary
or specialized healthcare organizations
for method removal or pregnancy
continued LARC use. This assumption is
in line with previous studies that esti-
mated real-life continuation rates.6,23
Using the Finnish national registers, we
minimized the risk of bias with non-
attenders common with all real-world
studies, because we combined removal
events based on records both in primary
and specialized care and identified
occurring pregnancies.MONTH 2020 AmAnother strength of the study is that
we analyzed first-time users of LARCs,
because only a woman’s first method was
provided free of charge. Without mostly
satisfied reinitiators, this study presents
discontinuation figures from an unse-
lected population of first-time LARC
users.
There are limitations to this study.
Data on LARC removals in private
healthcare were unavailable, unless
women used public health services after
placement. Women with more financial
assets have better access to private
healthcare. However, adherence to
family planning clinics is high and it is
likely that most women continue to use
the family planning services offered free
of charge. In addition, the public family
planning clinics in Vantaa are easily
accessible as part of primary care ser-
vices. The staff is experienced and sup-
ports the continuation of LARC use.
The results are generalizable only to
settings with similar types of services.
Our findings on women aged below 20
years should be interpreted with
caution because the number of womenerican Journal of Obstetrics & Gynecology 1.e9
Original Research GYNECOLOGY ajog.orgusing Cu-IUDs in this age group was
small.
Conclusion
The discontinuation rates of LARC
methods provided free of charge were
similar to those of previous findings from
mixed-payer settings. The LNG-IUS had
the lowest rate of discontinuation
compared with that of implants and Cu-
IUDs. At the end of 2 years, only 22%
of women had discontinued LNG-IUS
use. Young women and women with a
native language other than Finnish or
Swedish had higher rates of LARC
discontinuation. Thismay represent a gap
in counseling and knowledge of adverse
effects and attributes of the methods. The
reason for discontinuation was most
often bleeding disturbances, of which the
LNG-IUS had the lowest rate. This em-
phasizes the importance of an acceptable
bleeding profile in women and the
importance of addressing the expected
bleeding profiles in contraceptive coun-
seling. The present removal rates should
be acknowledged when designing con-
traceptive services providing free-of-
charge LARC methods. n
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SUPPLEMENTAL FIGURE 1
Cumulative 2-year discontinuation of LARC methods with those 1169 (58%)
women who visited the family planning clinics within the 2-year follow-up
Cu-IUD
Cu-IUD
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
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SUPPLEMENTAL FIGURE 2
Cumulative 2-year discontinuation of LARC methods in different age groups
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
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SUPPLEMENTAL TABLE 1
Characteristics of the study subjects divided according to LARC method and continuation status


















Age at LARC initiation, y
Median (IQR) 28.8 (23.5e34.0) 27.4 (22.0e32.0) 31.1 (26.0e35.3) 29.6 (25.0e33.5) 23.5 (19.8e29.4) 22.8 (19.1e29.0) 28.6 (25.0e33.4) 27.8 (25.0e31.0)
Age categories, y
15e19 164 (11) 73 (14) 35 (4) 14 (5) 124 (27) 59 (32) 5 (4) 0 (0)
20e29 664 (44) 258 (50) 376 (40) 126 (48) 223 (49) 91 (49) 65 (54) 41 (64)
30e44 684 (45) 183 (36) 525 (56) 123 (47) 108 (24) 37 (20) 51 (42) 23 (36)
Married 592 (39) 210 (41) 438 (47) 125 (48) 101 (22) 54 (29) 53 (44) 31 (48)
History of delivery 961 (64) 343 (67) 738 (79) 215 (82) 144 (32) 81 (43) 79 (65) 47 (73)
Delivery in the year preceding LARC
initiation
553 (37) 221 (43) 417 (45) 140 (53) 92 (20) 55 (29) 44 (36) 26 (41)
History of induced abortion 361 (24) 118 (23) 239 (26) 70 (27) 85 (19) 35 (19) 37 (31) 13 (20)
Induced abortion in the year
preceding LARC initiation
118 (8) 45 (9) 69 (7) 20 (8) 35 (8) 18 (10) 14 (12) 7 (11)
Socioeconomic statusa
Upper level employees 176 (12) 48 (9) 137 (15) 29 (11) 22 (5) 12 (6) 17 (14) 7 (11)
Lower level employees or manual
workers
886 (59) 285 (55) 574 (61) 154 (59) 243 (53) 97 (52) 69 (57) 34 (53)
Entrepreneurs, pensioners, or
unknown
147 (10) 59 (11) 92 (10) 28 (11) 47 (10) 22 (12) 8 (7) 9 (14)
Students 210 (14) 77 (15) 78 (8) 27 (10) 116 (25) 41 (22) 16 (13) 9 (14)
Long-term unemployed 85 (6) 43 (8) 51 (5) 23 (9) 24 (5) 15 (8) 10 (8) 5 (8)
Unavailable 8 (1) 2 (0) 4 (0) 2 (1) 3 (1) 0 (0) 1 (1) 0 (0)
Education level
Basic or unknownb 414 (27) 182 (35) 192 (21) 77 (29) 189 (42) 90 (48) 33 (27) 15 (23)
Longer (10 y or more) 1098 (73) 332 (65) 744 (79) 186 (71) 266 (58) 97 (52) 88 (73) 49 (77)
Basic education among women
aged 25 y or more
179 (12) 76 (15) 117 (12) 48 (18) 37 (8) 17 (9) 25 (21) 11 (17)
Native language Finnish or Swedish 1271 (84) 398 (77) 797 (85) 211 (80) 394 (87) 145 (78) 80 (66) 42 (66)
Sexually transmitted infectionc 37 (2) 24 (5) 15 (2) 10 (4) 22 (5) 12 (6) 0 (0) 2 (3)


































Characteristics of the study subjects divided according to LARC method and continuation status (continued)



















Yes 321 (21) 101 (20) 159 (17) 45 (17) 140 (31) 47 (25) 22 (18) 9 (14)
No 897 (59) 289 (56) 569 (61) 149 (57) 259 (57) 108 (58) 69 (57) 32 (50)
Unknown 294 (19) 124 (24) 208 (22) 69 (26) 56 (12) 32 (17) 30 (25) 23 (36)
Data are expressed as n (%) unless otherwise mentioned.
Cu-IUD, copper intrauterine device; IQR, interquartile range; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
a Socioeconomic status of the youngest age group can be derived from their family’s socioeconomic status; b Comprises women with only basic education (9-year mandatory education) and without education in Finland and those not graduating from elementary
school; c Chlamydia, gonorrhea, or syphilis 2 years before LARC initiation; d As entered in the electronic patient records within 2 years before LARC insertion.


































Crude and adjusted Poisson regression estimates of 2-year discontinuation rate ratios with Cu-IUD and implant
compared with LNG-IUS, and characteristics associated with discontinuation of all LARC methods for 1169 (58%)
women in the study cohort who visited the family planning clinics within 2 years after LARC initiation
LARC method Crude rate ratio (95% CI) P value Adjusted rate ratio (95% CI)a P value
LNG-IUS Ref. Ref.
Implant 1.92 (1.58e2.33) <.001 1.85 (1.49e2.31) <.001
Cu-IUD 1.59 (1.19e2.12) .002 1.52 (1.14e2.05) .005
Aged 30e44 y Ref. Ref.
Aged 20e29 y 1.32 (1.08e1.61) .007 1.16 (0.94e1.42) .161
Aged 15e19 y 1.60 (1.21e2.13) .001 1.26 (0.91e1.74) .162
Delivery in the year preceding LARC initiation
No Ref. Ref.
Yes 1.10 (0.92e1.32) .291 1.27 (1.04e1.55) .017
Native language Finnish or Swedish
Yes Ref. Ref.
No 1.36 (1.10e1.68) .005 1.30 (1.04e1.62) .020
Sexually transmitted infectionb
No Ref. Ref.
Yes 1.59 (1.05e2.42) .030 1.36 (0.88e2.09) .169
CI, confidence interval; Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system; Ref., reference.
a Adjusted with categorical age, giving birth within the year preceding LARC initiation, mother tongue, and STI 2 years before LARC initiation; b Chlamydia, gonorrhea, or syphilis 2 years before LARC
initiation.
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SUPPLEMENTAL TABLE 3
Cumulative discontinuation rate per 100 women-years of LARC methods in different age groups
Age LNG-IUS Implant Cu-IUD
15e19 y 33.0 (20.6, 50.0) 36.1 (29.1, 44.1) -
20e29 y 28.7 (24.6, 33.2) 34.1 (28.7, 40.3) 42.4 (33.2, 53.0)
30e44 y 20.3 (17.3, 23.8) 28.3 (21.4, 36.9) 33.7 (23.7, 46.3)
All age groups 24.2 (21.7, 26.9), 33.3 (29.5, 37.4) 37.8 (31.0, 45.7)
Data are presented as mean (95% confidence intervals).
Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system.
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SUPPLEMENTAL TABLE 4
Crude and adjusted Poisson regression estimates of 2-year discontinuation rate ratios with Cu-IUD and implant
compared with LNG-IUS and characteristics associated with discontinuation
Crude rate ratio (95% CI) P value Adjusted rate ratio (95% CI)a P value
LARC method
LNG-IUS Ref. Ref.
Implant 1.36 (1.10e1.68) .005 1.29 (1.04e1.62) .023
Cu-IUD 1.90 (1.44e2.49) <.001 1.76 (1.32e2.33) <.001
Aged 30e44 y Ref. Ref.
Aged 20e29 y 1.46 (1.21e1.76) <.001 1.34 (1.10e1.63) .005
Delivery in the year preceding LARC initiation
No Ref. Ref.
Yes 1.33 (1.10e1.60) .003 1.37 (1.13e1.67) .001
Native language, Finnish or Swedish
Yes Ref. Ref.
No 1.47 (1.19e1.83) <.001 1.33 (1.06e1.66) .014
Sexually transmitted infectionb
No Ref. Ref.
Yes 1.77 (1.13e2.77) .013 1.73 (1.09e2.73) .020
Socioeconomic status
Upper level employees Ref.
Lower level employees or manual workers 1.11 (0.81e1.52) .503
Entrepreneurs, pensioners, or unknown 1.29 (0.87e1.92) .212
Students 1.36 (0.91e2.05) .138
Long-term unemployed 1.62 (1.05e2.49) .028
Unavailable 1.40 (0.34e5.78) .640
Education level
Longer (10 y or more) Ref.
Basic (9-y mandatory education) or unknown 1.29 (1.04e1.59) .019
Marital status
Married Ref.
Not married 0.95 (0.78e1.14) .564
History of delivery
No Ref.
Yes 1.14 (0.92e1.42) .225
History of induced abortion
No Ref.
Yes 0.91 (0.74e1.14) .421
Induced abortion in the year preceding LARC initiation
No Ref.
Yes 1.02 (0.72e1.43) .919
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SUPPLEMENTAL TABLE 4
Crude and adjusted Poisson regression estimates of 2-year discontinuation rate ratios with Cu-IUD and implant
compared with LNG-IUS and characteristics associated with discontinuation (continued)
Crude rate ratio (95% CI) P value Adjusted rate ratio (95% CI)a P value
Only basic education among women aged 25 y or more
No Ref.
Yes 1.26 (0.98e1.61) .070
Smoking within the past 2 y
No Ref.
Yes 0.91 (0.70e1.17) .455
Only women aged 20 to 44 years are included (n¼1789).
CI, confidence interval; Cu-IUD, copper intrauterine device; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system; Ref., reference.
a Adjusted with categorical age, delivery in the year preceding LARC initiation, mother tongue, and STI 2 years before LARC initiation; b Chlamydia, gonorrhea, or syphilis 2 years before LARC
initiation.
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